Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2020-01-13 Declaration of Voting R…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' by The Goldman Sachs Group, Inc. in Evotec SE, referencing specific sections of the German Securities Trading Act (WpHG). This type of filing, which reports changes in significant share ownership thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via DGAP (which might suggest RNS), the specific content dictates the MRQ classification over the general regulatory fallback.
2020-01-13 English
BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON POLYCYSTIC OVARY SYNDROME
Regulatory Filings Classification · 100% confidence The document is a press release dated January 9, 2020, announcing a new strategic alliance between Evotec SE and Bayer AG regarding drug development for Polycystic Ovary Syndrome (PCOS). It details the terms, financial considerations (milestone payments, upfront payments), and background information on the companies and the medical condition. This type of announcement, detailing a significant business development, partnership, or strategic move that is not a routine financial report (like 10-K, IR, or ER), typically falls under general corporate news or regulatory filings. Since it is a specific announcement of a business transaction/collaboration, it is best classified as a general Regulatory Filing (RNS) as it is disseminated via DGAP (a service for regulatory announcements) and does not fit the more specific categories like Capital/Financing Update (CAP) or M&A Activity (TAR). It is a news release about a corporate event.
2020-01-09 English
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' in Evotec SE by The Goldman Sachs Group, Inc. It specifies the date the threshold was crossed (03 Jan 2020) and details the resulting percentage of voting rights attached to shares and instruments. This content directly corresponds to the definition of reporting changes in significant share ownership levels, which maps to the Major Shareholding Notification category.
2020-01-08 English
EVOTEC AND BRISTOL-MYERS SQUIBB EXPAND IPSC COLLABORATION
Environmental & Social Information Classification · 99% confidence The document is a press release dated January 7, 2020, announcing an expansion of a collaboration between Evotec SE and Bristol-Myers Squibb, which triggered a US$ 6 million payment to Evotec. It discusses scientific progress (iPSC technology) and partnership details, rather than reporting periodic financial results (like 10-K or IR), announcing a management change (MANG), or detailing insider trading (DIRS). This type of announcement, which is a general corporate update regarding business development and strategic milestones, fits best under the general 'Regulatory Filings' (RNS) category, as it is a news release disseminated via DGAP (a service for regulatory announcements and corporate news) that doesn't fit the more specific categories like CAP, TAR, or ER. It is not a short announcement pointing to a larger report, so RPA is not appropriate.
2020-01-07 English
EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
Report Publication Announcement Classification · 99% confidence The document is a press release dated January 2, 2020, announcing that Evotec SE management will be presenting at and attending several upcoming investor conferences in January and February 2020 (e.g., ODDO BHF Forum, J.P. Morgan Healthcare Conference). This type of announcement, detailing management's schedule for investor outreach and presentations at industry events, is best classified as Investor Presentation (IP) material, as it directly relates to investor engagement and future outlook discussions, even though it is an announcement of attendance rather than the presentation itself. However, since the document is an announcement about *attending* conferences where presentations will occur, and it is not a formal regulatory filing like 10-K or a specific financial report, it fits best under the general category of investor relations communication. Given the options, 'Investor Presentation (IP)' is the most relevant category for communications detailing management's schedule for engaging with investors at conferences, even if it's just an announcement of attendance. It is not a Report Publication Announcement (RPA) because it is not announcing the publication of a formal financial report (like an annual or quarterly report).
2020-01-02 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Evotec SE: Release according to Article 41 of the WpHG' and specifically announces the 'Publication of total number of voting rights' following a 'Conditional capital increase'. This type of announcement, dealing with changes in the total number of voting rights due to capital structure changes (like conditional capital increases), fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if no other specific code applies. However, since it details a specific capital measure (conditional capital increase) and the resulting total voting rights, it is a direct update on the company's capital structure. Given the options, 'CAP' (Capital/Financing Update) is the most precise fit for reporting changes related to capital increases and total voting rights resulting from them, although 'RNS' is also plausible as a general regulatory announcement. Since the core subject is the capital structure change leading to a new total voting rights count, CAP is selected over the general RNS fallback. The document length is short, but it is the primary announcement itself, not an announcement *of* another report.
2019-12-30 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.